Welcome to Protein Degradation & Targeting Undruggables European Congress Europe
The Congress returns to bring together leading experts and researchers from the field of targeted protein degradation and beyond to explore the latest advancements and therapeutic opportunities supporting successful clinical translation of candidates.
There is an emerging message that stemming from the success of occupancy driven pharmacology in the clinic and the opportunities unfolding from the event driven pharmacology space with promise to unlock the undruggable space further. However, challenges remain and will be addressed in this meeting in areas such as finding new E3 ligases and ligands, rational discovery and characterization of molecular glues, optimized PROTAC safety and PK/PD, and induced proximity concepts and therapeutic applicability.
Coupled with opportunities to elevate the quality of discussions and networking opportunities through our workshops, challenge roundtables and investor perspectives, the 5th Annual Protein Degradation & Targeting Undruggables Congress: Europe provides an unmissable experience towards optimising your research outcomes, pipeline viability and therapeutic success across diverse indications.
2023 Speakers
Markus Queisser
Natasa Zamurovic
Graham Simpson
Andreas Reichel
Gwenn Hansen
Brad Enerson
Luc Brunsveld
Manfred Koegl
Manfred Koegl is a director in Oncology Research in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. Presently, his team focuses on targeted protein degradation in cancer cell signaling.
Before 2010, he worked at the German Cancer Research Center in Heidelberg, Germany. He has worked at several small biotech companies in Heidelberg, including Phenex Pharmaceuticals. Manfred Koegl studied biology in Vienna and received his PhD in cell biology in 1994 at the EMBL, Heidelberg.
Greg Hollingworth
Adam Gilbert
Kevin Moreau
Mary Matyskiela
Ted Suh
Michael Plewe
Michael Plewe is SVP - Medicinal Chemistry at Cullgen Inc., a company dedicated to the development of novel E3 ligands for targeted protein degradation in oncology and immune disease. Before joining Cullgen in 2018, he was the Head of Chemistry at Arisan Therapeutics, a start-up focused on developing novel treatments for neglected viral diseases. Prior to Arisan, he was an Associate Research Fellow and project leader at Pfizer Inc. working in multiple therapeutic areas including oncology, ophthalmology, diabetes, and infectious diseases such as HIV. He was a medicinal chemist at Agouron and at Vical, a gene therapy company. Dr. Plewe completed his postdoctoral training at the University of California at Irvine and earned his Ph. D. and Diploma in organic chemistry from the University of Konstanz in Germany.
Alzbeta Tuerkova
Hyunsun Jo
Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio. He obtained his BA and PhD in Molecular Biology (Metabolic Diseases) at Seoul National University and Postdoc (aging-related diseases) at the Gladstone Institute (UCSF).
Giovanni Spagnolli
Matthias Brand
Nicki Thompson
Ryoma Hara
Ian Churcher
Marcus Hartmann
Erin Dueber
Merve Mutlu
Heide Marika Düvel
Caroline Rynn
Martin Hemmerling
Jacob Aguirre
Benedict Cross
Fiona Sorrell
Konstantinos Tzelepis
Dennis Gillingham
Previous Attendees Include
Delegate Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket price will increase after
— June 16, 2023 —
Download the exclusive 2023 agenda
Download the agenda for the Protein Degradation & Targeting Undruggables Congress Europe 2023!
Download the agenda
Attendee Testimonials
2023 Partners
Platinum Sponsor
Pelago Bioscience AB
Website: https://www.pelagobio.com/
Pelago Bioscience AB established in 2013 provides and develops the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions, to accelerate drug discovery and diagnostics development. CETSA® provides a quantitative measure of target engagement and the biophysical readout of affinity, and adds real value to existing efficacy assays. We deliver complete target engagement hit confirmation data sets, develop and validate assays for use in screening cascades, and profile candidate drugs based on the CETSA® method, tailored to the project need.
Promega
Website: https://www.promega.com
Promega is committed to excellence in technologies and compound profiling services to assess key processes in Targeted Protein Degradation and Induced Proximity mechanisms. From assessing protein degradation in real time, to understanding compound binding and permeability, to ternary complex formation and more. Our CRIPSR HiBiT content covers hundreds of pre-built targets. Novel software analysis tools allow for the determination of target protein degradation rates, DC50 potency values, recovery profiles and more.
Silver Sponsors
Exhibitor
Proteome Sciences
Website: https://www.proteomics.com/
Proteome Sciences is a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications.
By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, we can detect over 8,000 proteins per sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated in either disease progression or drug treatment.
Using our unique TMTpro isobaric mass tags, we can run up to 15 samples per single experiment thereby allowing relative protein quantification between samples. By using a reference channel, multiple experiments can be performed sequentially, thereby allowing 30 to 100+ samples to be characterized in one project. Sensitivity is equivalent to conventional ELISA in many cases.
In the clinical area, we offer single or multiplexed protein measurements on customer selected proteins either with or without a PTM. Proteins selected can be either known previously, or more often detected above via our Discovery Services. We can measure up to 100 multiplex proteins per sample in a GCLP accredited Targeted Mass Spectrometric assay using clinically relevant samples such as plasma and CSF. Again, sensitivity is equivalent to conventional ELISA in many cases.
Media Partners
Select Science
Website: https://www.selectscience.net/
Please visit our website for more information.Drug Discovery World
Website: https://www.ddw-online.com/
Drug Discovery World is the multi-platform global voice for the drug discovery community. From research stage to clinical trials the brand covers the scientific and commercial process involved in getting a drug to market–research, target identification and validation, drug molecule identification, lead molecule optimisation, pre-clinical research, clinical trial authorisation and application, and clinical trials phase I and II. DDW readers learn how to turn science into business.
DDW is available as a quarterly printed publication, online and as a free-to-download app containing trusted content as well as premium hand-picked intelligence for anyone involved in drug discovery and development. Readers can also sign up for our free weekly e-newsletter.
From bench through to boardroom DDW offers commercial insight for researchers, scientists and decision-makers involved in drug discovery and development. We cover the latest news and events in the global pharmaceutical, biopharmaceutical and biotech sectors, as well as the technology and processes to help create vaccines, therapeutics and drugs.
pharmaphorum
Website: https://pharmaphorum.com/
pharmaphorum is a content and communications company offering a unique hybrid of publisher and agency working in pharma and healthcare.
pharmaphorum.com is our own independent flagship publication. It serves over 3 million unique users annually and its news and information is widely recognised as a leading source of thought leadership and strategic content for pharmaceutical professionals all over the world.
Our innovative digital magazine Deep Dive provides cutting edge insight on pharma industry trends to an audience of 100K per issue.
World Pharma Today
Website: https://www.worldpharmatoday.com/
Please visit our website for more information.Become a partner
Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.
Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.
Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.
Find out more by calling us at +44 (0)20 3696 2920 or email Jack Tollervey at [email protected]
Protein Degradation Media Kit
For more information on webinars, roundtables, content marketing packages, interviews and bespoke opportunities to accelerate Protein dedgradation innovation, download the Media Kit below.
If you have any questions, please contact Simon Pickles, Senior Commercial Partnerships Manager, [email protected].
Poster Session
Looking to showcase your recent work to the protein degradation community?
Our dedicated poster session is the perfect way to get your research noticed. Ideal for PhD students or Post-Doctoral researchers.
In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area.
Applications closes 18 August 2023.
Abstracts received after this time may not be accepted so please submit your abstract here.
Kisaco Research will provide boards and fixings. Delegates are responsible for bringing the copy of their poster to be presented. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.
Highlights from previous years
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.